INTRODUCTION: Hemostatic powder (TC-325) is a new tool for treatment of gastrointestinal bleeding that allows the treatment of large surfaces with active bleeding. The aim was to describe the initial success of TC-325 for the control of GI bleeding. MATERIALS AND METHODS: We did a multicenter cohort study with patients admitted to the endoscopy service for GI bleeding. A format was generated to standardize the information obtained in each center. It was determined whether this treatment had been used as a single therapy or as a combination therapy. Descriptive statistics with medians and ranges, or averages with SD according to distribution. RESULTS: Eighty-one patients with 104 endoscopic procedures were included. The median number of endoscopic procedures was 1 (1-3). In the first procedure, the initial success rate was 98.8% (n = 80), failure rate was 1.2% (n = 1), and rebleeding rate was 20% (n = 16). The majority of rebleeding cases occurred within the first 3 days (12/16, 75%). There was no association between rebleeding and etiology (malignant or benign; P = 0.6). In first procedure, 44 (54%) cases had monotherapy with TC-325 and 37 (46%) cases had a combined endoscopic therapy. There were no differences in initial success or rebleeding rates when TC-325 was used as monotherapy versus combined therapy (P = 0.7). The mortality rate was 4% (3/81). CONCLUSION: TC-325 is effective for achieving initial control of bleeding in patients with different GI etiologies. The rate of bleeding recurrence is considerable in both patients with benign and malignant etiology.
INTRODUCTION: Hemostatic powder (TC-325) is a new tool for treatment of gastrointestinal bleeding that allows the treatment of large surfaces with active bleeding. The aim was to describe the initial success of TC-325 for the control of GI bleeding. MATERIALS AND METHODS: We did a multicenter cohort study with patients admitted to the endoscopy service for GI bleeding. A format was generated to standardize the information obtained in each center. It was determined whether this treatment had been used as a single therapy or as a combination therapy. Descriptive statistics with medians and ranges, or averages with SD according to distribution. RESULTS: Eighty-one patients with 104 endoscopic procedures were included. The median number of endoscopic procedures was 1 (1-3). In the first procedure, the initial success rate was 98.8% (n = 80), failure rate was 1.2% (n = 1), and rebleeding rate was 20% (n = 16). The majority of rebleeding cases occurred within the first 3 days (12/16, 75%). There was no association between rebleeding and etiology (malignant or benign; P = 0.6). In first procedure, 44 (54%) cases had monotherapy with TC-325 and 37 (46%) cases had a combined endoscopic therapy. There were no differences in initial success or rebleeding rates when TC-325 was used as monotherapy versus combined therapy (P = 0.7). The mortality rate was 4% (3/81). CONCLUSION:TC-325 is effective for achieving initial control of bleeding in patients with different GI etiologies. The rate of bleeding recurrence is considerable in both patients with benign and malignant etiology.
Entities:
Keywords:
Active bleeding; Gastrointestinal bleeding; Hemostatic powder; Mexico; TC-325
Authors: Louis-Michel Wong Kee Song; Subhas Banerjee; Bradley A Barth; Yasser Bhat; David Desilets; Klaus T Gottlieb; John T Maple; Patrick R Pfau; Douglas K Pleskow; Uzma D Siddiqui; Jeffrey L Tokar; Amy Wang; Sarah A Rodriguez Journal: Gastrointest Endosc Date: 2012-03-23 Impact factor: 9.427
Authors: Ian M Gralnek; Jean-Marc Dumonceau; Ernst J Kuipers; Angel Lanas; David S Sanders; Matthew Kurien; Gianluca Rotondano; Tomas Hucl; Mario Dinis-Ribeiro; Riccardo Marmo; Istvan Racz; Alberto Arezzo; Ralf-Thorsten Hoffmann; Gilles Lesur; Roberto de Franchis; Lars Aabakken; Andrew Veitch; Franco Radaelli; Paulo Salgueiro; Ricardo Cardoso; Luís Maia; Angelo Zullo; Livio Cipolletta; Cesare Hassan Journal: Endoscopy Date: 2015-09-29 Impact factor: 10.093